HIV-1 drug resistance: can we overcome? (Q34974754)

5 August 2017

1 reference

title

HIV-1 drug resistance: can we overcome? (English)

1 reference

5 August 2017

Mark A Wainberg

1 reference

5 August 2017

Bluma G Brenner

1 reference

5 August 2017

Dan Turner

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Biological Therapy

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

751-761

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Estimating relative fitness in viral competition experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Structured treatment interruptions in antiretroviral management of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Structured Treatment Interruption: Approaches and Risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

Impact of drug resistance mutations on virologic response to salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.751

21 January 2018

Identifiers

DOI

10.1517/14712598.2.7.751

1 reference

5 August 2017

1 reference